The government has started a panel to discover means to establish inexpensive drugs for the common public and in this view, Center asked to revisit pharmaceutical pricing rules.
Department of pharmaceuticals has asked the panel to advise policy actions that can be announced in the drug rule to discourage companies from overpricing customers on pharmaceutical produces. Also, the panel has asked for advice on the penalty which can be imposed on pharmaceutical companies.
Healthcare disbursements are rising which is resulting in the burden of critical diseases like diabetes and hypertension which does need to continue with medication throughout patient lives.
The panel will have six members consisting NPPA, DCGI, and others.